Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma - Takeaways - MDSpire

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

  • By

  • Christen M. Dillard

  • Hans Lee

  • Nilesh Kalariya

  • Naveen Subramanian

  • Oren Pasvolsky

  • Christopher Ferreri

  • Mahmoud Gaballa

  • Sheeba K. Thomas

  • Donna M. Weber

  • Melody Becnel

  • Gregory Kaufman

  • Muzaffar Qazilbash

  • Robert Z. Orlowski

  • Michelle A. T. Hildebrandt

  • Krina K. Patel

  • April 13, 2026

  • 0 min

Share

  • 1

    Idecabtagene vicleucel shows high efficacy in relapsed/refractory multiple myeloma, with overall response rates between 73-100%.

  • 2

    Racial and ethnic minorities are underrepresented in clinical trials, creating gaps in understanding CAR-T therapy's safety and efficacy.

  • 3

    Genetic ancestry may provide a more accurate measure of factors influencing CAR-T outcomes than traditional racial and ethnic categories.

  • 4

    Patients with higher African ancestry exhibited more aggressive disease features, while those with higher European ancestry had better performance status.

  • 5

    No significant differences in overall response rates, progression-free survival, or overall survival were found based on genetic ancestry.

Original Source(s)

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

  • by Christen M. Dillard, Hans Lee, Nilesh Kalariya, Naveen Subramanian, Oren Pasvolsky, Christopher Ferreri, Mahmoud Gaballa, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Gregory Kaufman, Muzaffar Qazilbash, Robert Z. Orlowski, Michelle A. T. Hildebrandt, Krina K. Patel

  • April 13, 2026

Related Content

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders

AstraZeneca Deepens China Cell Therapy Push

New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration

  • March 31, 2026

  • 2 min
Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders